Description
SWOT ANALYSIS OF ROCHE HOLDINGS
Roche Holding
Parent Company
Roche Holding
Category
Pharmaceutical
Sector
Health Care
Tagline/ Slogan
We innovate healthcare
Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals – from early detection and prevention of diseases to diagnosis, treatment, and treatment USP monitoring.
STP
Segment
Pharmaceutical & medical diagnostic segment
Patients & healthcare professionals seeking detection, prevention & Target Group treatment of disease
Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to Positioning patients and healthcare professionals
SWOT Analysis
1. Over 80,00 employees present all over the world including Africa, America, Europe, Asia, Australia. 2.It is one of the world’s leading supplier of cancer medicines and the number one in vitro diagnostics company. 3.Innovation through a focus on R&D on pharmaceuticals and diagnostics 4.Only drug company authorized to manufacture oseltamivir(Tamiflu), a drug against avian/swineflu. 5. It is the biggest biotechnology company, with 14 biological products on the market 6. Has collaborated with big pharma companies for effective operations Strength and R&D
Weakness
1. Imitation of products/ fake medicines supplied under brands name can affect brand
2. Products may be available only in certain countries
1.Strategic agreements with other pharmaceutical companies and organizations to boost its research. 2. Increasing awareness about healthcare needs 3. Global penetration through mergers and acquisitions Opportunity 4. Increasing demand for quality healthcare solutions
1.Risk of unsuccessful new Products 2.Regulatory environment is becoming more & more stringent Threats 3.Economic slowdown and global financial fluctuations
Competition
1. Siemens Healthcare 2.Bayer life sciences 3.Abbot Laboratories Competitors 4. Sanofi Aventis
doc_558479288.docx
SWOT ANALYSIS OF ROCHE HOLDINGS
Roche Holding
Parent Company
Roche Holding
Category
Pharmaceutical
Sector
Health Care
Tagline/ Slogan
We innovate healthcare
Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals – from early detection and prevention of diseases to diagnosis, treatment, and treatment USP monitoring.
STP
Segment
Pharmaceutical & medical diagnostic segment
Patients & healthcare professionals seeking detection, prevention & Target Group treatment of disease
Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to Positioning patients and healthcare professionals
SWOT Analysis
1. Over 80,00 employees present all over the world including Africa, America, Europe, Asia, Australia. 2.It is one of the world’s leading supplier of cancer medicines and the number one in vitro diagnostics company. 3.Innovation through a focus on R&D on pharmaceuticals and diagnostics 4.Only drug company authorized to manufacture oseltamivir(Tamiflu), a drug against avian/swineflu. 5. It is the biggest biotechnology company, with 14 biological products on the market 6. Has collaborated with big pharma companies for effective operations Strength and R&D
Weakness
1. Imitation of products/ fake medicines supplied under brands name can affect brand
2. Products may be available only in certain countries
1.Strategic agreements with other pharmaceutical companies and organizations to boost its research. 2. Increasing awareness about healthcare needs 3. Global penetration through mergers and acquisitions Opportunity 4. Increasing demand for quality healthcare solutions
1.Risk of unsuccessful new Products 2.Regulatory environment is becoming more & more stringent Threats 3.Economic slowdown and global financial fluctuations
Competition
1. Siemens Healthcare 2.Bayer life sciences 3.Abbot Laboratories Competitors 4. Sanofi Aventis
doc_558479288.docx